QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers

by | Mar 12, 2025 | Clinical Trials | 0 comments

​ 

/PRNewswire/ — QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that…

 /PRNewswire/ — QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that… 

Submit a Comment

Your email address will not be published. Required fields are marked *